I’ve a Feeling Dapagliflozin Isn’t in Kansas Anymore

I’ve a Feeling Dapagliflozin Isn’t in Kansas Anymore

This course is a recording of our Journal Club. Join us on the second Wednesday of every month for our live session of Journal Club! Each month, you’ll earn 1 hour of live CE, stay up to date with the latest literature, and build your confidence to evaluate the next landmark trial.

Here’s how it works:
1. Review the Study
2. Complete the Study Guide
3. Discover answers & improve patient care during our Journal Club recording

Tune in to find out: Should you use a diabetes medication in a patient without diabetes?
A recent NEJM publication supports the use of SGLT2 inhibitors in patients with heart failure but without a diabetes diagnosis. Join October’s Journal Club, lead by Dr. Raven Jackson, PharmD to learn how a historically ‘diabetes drug’ may now benefit a new patient population.

Upon successful completion of this application-based course, pharmacists and students should be able to:
1. Explain the role of dapagliflozin in the treatment of diabetes.
2. Discuss the role of dapagliflozin in the treatment of heart failure
3. Discuss the results and conclusions of a clinical trial
4. Develop treatment recommendations based on the DAPA-HF trial
5. Review clinical appropriateness of dapagliflozin for the treatment of diabetes or heart failure

Raven Jackson, PharmD
Clinical Assistant Professor
Division of Clinical and Administrative Sciences
College of Pharmacy
Xavier University of Louisiana

Raven Jackson does not report any actual or potential conflicts of interest in relation to this continuing pharmacy education course. 

CEimpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read:

McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019;381:1995-2008.

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Initial Release Date: October 14, 2020
Planned Expiration Date: October 14, 2023

Universal Activity Number (UAN): 0107-0000-20-280-H01-P
Application-based CPE Activity

CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at www.MyCPEMonitor.net.

¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.

Additional information

Duration

1h 0m

Topic Designator

Disease State/Drug Therapy

ACPE

Yes

ACPE Topic

01 Drug Therapy

Role

Pharmacist

Media-Type

On-Demand

Release Date

10/14/20

CEUs

0.1

Rating

4

ACPE Number

0107-0000-20-280-H01-P

This course is in our subscription.

0